The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.
The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in ...
The preventive immunization Nous-209 works in an initial trial with patients who have 17 times the risk of developing tumors ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification ...
Table 1. Summary of clinicopathologic features evaluated in the different models to predict MMR deficiency ...
When Vanessa was diagnosed with advanced colon cancer in 2014, just before her 60th birthday, the mother and grandmother learned the cancer had already spread to her stomach and liver. Even after a ...
Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results